- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05128721
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults
연구 개요
상세 설명
This is a Phase I, Randomized, Open-Labeled Clinical trial. Eligible volunteers will be randomized in a 1:1:1 allocation ratio, into one of the three study arms using the Interactive Web Response Technology (IWRS).
Unscheduled visits can occur at any time during the study period outside the initially planned study visits, all the extra visits will be documented in the subjects' files. Volunteers will be randomized into one of the following arms to receive different doses of the Inactivated
SARS-COV-2 Vaccine "NRC-VACC-101" as an intramuscular (IM) Injection or Placebo:
Arm One:
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
Arm Two:
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
Arm Three (Control arm):
Volunteers will receive two IM doses of the placebo, 28 days apart. The first 9 subjects will be initially vaccinated with their first dose, as per their assigned study arm determined by the randomization procedures and will be followed up until day 14 (visit 03). At this point in the study, the Data Safety and Monitoring Board (DSMB) will review safety data before proceeding with vaccinating the rest of the recruited subjects
연구 유형
등록 (예상)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Osama Azmy, MD
- 전화번호: +201223103084
- 이메일: osamaazmy@yahoo.com
연구 연락처 백업
- 이름: Clinical Trial Unit Clinical Trial Unit National Research Centre, MD
- 전화번호: +20237623009
- 이메일: ctu.mrce@nrc.sci.eg
연구 장소
-
-
Giza
-
Cairo, Giza, 이집트, 12622
- 모병
- Medical Research Centre of Excellence National Research Centre
-
연락하다:
- Osama Azmy, MD
- 전화번호: +201223103084
- 이메일: osamaazmy@yahoo.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults with age 18 to 50 years.
- Willingness.
- For married females of childbearing age: Willingness to practice continuous effective contraception for one year from the start of the study.
- Agreement to refrain from blood donation during the study.
- Body temperature is within the normal range (36.5 - 37.5°C).
- General good health as established by medical history, physical and laboratory examinations.
Exclusion Criteria:
- Pregnancy or lactation.
- Inability to provide informed consent.
- Recent receipt of any vaccination within 30 days prior to baseline.
- Planning to receive any vaccination during the course of the study.
- Prior receipt of Adenovirus vaccine, or any other Coronavirus vaccine.
- Recent receipt of any immunoglobulin within 90 days prior to baseline.
- Recent receipt of any blood product within 90 days prior to baseline.
Volunteers who are immunosuppressed or receiving immunosuppressive medications, including:
HIV infection, asplenia, recurrent severe infections, and the use of immunosuppressive medications within the past 6 months, except for topical steroids or short-term oral steroids (course lasting < 14 days).
- Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
- Having any autoimmune disease.
- History of allergic reactions for any of the vaccine components.
- History of angioedema.
- History of anaphylaxis.
- History of cancer.
- History of serious psychiatric conditions that are likely to affect participation in the study.
- Having bleeding disorders.
- Having chronic respiratory diseases.
- Having chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorders, and neurological illness.
- Volunteers with BMI ≥ 40 Kg/m2 or ≤ 18 Kg/m2.
- Current alcohol abuse.
- Drug abuse within 5 years prior to baseline.
- History of laboratory-confirmed COVID-19 or seropositivity for SARS-CoV-2 or positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS CoV-2 or abnormal chest CT-Scan (COVID-19 image) or positive pharyngeal/sputum swabs for SARS-CoV-2.
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
- High-risk population (volunteers who work in front-line health facilities or were in close contact with confirmed COVID-19 cases).
- Living in the same household as anyone at high risk of severe COVID-19.
- Any condition, according to the judgment of the investigator, that would interfere with the subject's ability to comply with all study requirements or that would place the subject at unacceptable risk by his/her participation in the study or impair the interpretation of the study data.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: NRC-VACC-101 vaccine 3 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
다른 이름들:
|
활성 비교기: NRC-VACC-101 vaccine 6 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
다른 이름들:
|
위약 비교기: Control arm
Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
The safety of NRC-VACC-101 Vaccine
기간: Follow up for any solicited adverse event(AE) reported within 7 days
|
To evaluate the safety of the proposed regimens of NRC-VACC-101
|
Follow up for any solicited adverse event(AE) reported within 7 days
|
The tolerability of NRC-VACC-101 Vaccine
기간: Follow up for any AE within 28 days of each dose
|
To evaluate the tolerability of the proposed regimens of NRC-VACC-101 Vaccine in the healthy population
|
Follow up for any AE within 28 days of each dose
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
The seroconversion rate of neutralizing antibodies
기간: The evaluation of the antibody will be measured up to one month of each dose
|
To evaluate the seroconversion rate of neutralizing antibodies resulting from the NRC-VACC-101 Vaccine
|
The evaluation of the antibody will be measured up to one month of each dose
|
To recommend the dose level of NRC-VACC-101 Vaccine for the phase II trial.
기간: The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
The evaluation of the Microneutralization Assay curve will give an overview of the dose possible suggested dose of NRC-VACC-101 Vaccine for the phase II trial
|
The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Osama Azmy, MD, Medical Research and Clinical Studies Institute National Research Centre, Dokki, Giza, Egypt.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- NO-B041
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
코로나바이러스감염증-19 : 코로나19에 대한 임상 시험
-
Yang I. Pachankis모집하지 않고 적극적으로COVID-19 호흡기 감염 | COVID-19 스트레스 증후군 | COVID-19 백신 부작용 | COVID-19 관련 혈전색전증 | COVID-19 집중 치료 후 증후군 | COVID-19 관련 뇌졸중중국
-
Endourage, LLC모병긴 COVID | 긴 Covid19 | 포스트 급성 COVID-19 | 장거리 COVID | 장거리 COVID-19 | COVID-19 후 증후군미국
-
Massachusetts General Hospital모병
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of Ioannina모병COVID-19 폐렴 | COVID-19 호흡기 감염 | 코로나19 감염병 세계적 유행 | COVID-19 급성호흡곤란증후군 | COVID-19 관련 폐렴 | COVID 19 관련 응고병증 | COVID-19(코로나바이러스 질병 2019) | COVID-19 관련 혈전색전증그리스
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention...완전한
-
Jonathann Kuo, MD모집하지 않고 적극적으로SARS-CoV2 감염 | 코로나19 이후 증후군 | 자율신경실조증 | 급성 COVID-19 후 증후군 | 긴 COVID | 긴 Covid19 | COVID-19 재발 | 포스트 급성 COVID-19 | 급성 COVID-19 감염 후 | COVID-19의 급성 후유증 | 자율신경실조증 유사 장애 | 자율신경실조증 기립성 저혈압 증후군 | COVID-19 이후 상태 | 포스트 코로나 증후군 | COVID-19 이후 상태, 지정되지 않음미국
-
Patrick Robinson모병코로나19 | COVID-19 폐렴 | COVID-19 호흡기 감염 | COVID-19 급성 기관지염미국
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.완전한
Covi Vax에 대한 임상 시험
-
Sorrento Therapeutics, Inc.빼는
-
Sorrento Therapeutics, Inc.빼는
-
Chonnam National University Hospital알려지지 않은
-
Entos Pharmaceuticals Inc.Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma Solutions... 그리고 다른 협력자들완전한
-
University of PennsylvaniaPhiladelphia Department of Public Health완전한
-
Sorrento Therapeutics, Inc.빼는급성 호흡기 장애 증후군 | 급성호흡곤란증후군